Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.35 |
| ▸ | NPY1R | P25929 | 2/20 | 0.33 |
| ▸ | NPY4R | P50391 | 2/20 | 0.33 |
| ▸ | FURIN | P09958 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18272909 | 1.00 | GLP1R (0.35) | GLP1RNPY1RNPY4RFURINRXFP1 | |
| SCHEMBL18272906 | 1.00 | GLP1R (0.35) | GLP1RNPY1RNPY4RFURINRXFP1 | |
| SCHEMBL18272904 | 0.99 | GLP1R (0.34) | GLP1RNPY1RNPY4RFURINRXFP1 | |
| SCHEMBL24453927 | 0.92 | FURIN (0.34) | FURINRXFP1C3AR1CASP1CTSL | |
| SCHEMBL23682548 | 0.92 | FURIN (0.34) | FURINRXFP1C3AR1CASP1CTSL | |
| SCHEMBL23682535 | 0.92 | FURIN (0.34) | FURINRXFP1C3AR1CASP1CTSL | |
| SCHEMBL18272907 | 0.91 | FURIN (0.38) | GLP1RNPY1RNPY4RFURINRXFP1 | |
| SCHEMBL18272908 | 0.91 | FURIN (0.38) | GLP1RNPY1RNPY4RFURINRXFP1 | |
| SCHEMBL26717314 | 0.90 | FURIN (0.38) | GLP1RFURINRXFP1CTSL | |
| SCHEMBL18909042 | 0.85 | FAP (0.33) | GLP1RNPY1RNPY4RC3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma AG (DE) | 2018-07-05 | — | — | US | disclosed |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | GLP1R 4843/4885NPY1R 4872/4885NPY4R 4884/4885 |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | GLP1R 4497/4885NPY1R 4460/4885NPY4R 4310/4885 |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | TNFSF11, TNFRSF9, CD40 | GLP1R 2891/4885NPY1R 4080/4885NPY4R 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.